Expertise in
11
conditions

Dr. Minsig K. Choi

Oncology
Oncology-Edgewood Cancer Center-St. Elizabeth Healthcare
1 Medical Village Dr, 
Edgewood, KY 
Accepting New Patients
Expertise in
11
conditions
Oncology-Edgewood Cancer Center-St. Elizabeth Healthcare
1 Medical Village Dr, 
Edgewood, KY 

Overview

Minsig Choi is an Oncologist practicing medicine in Edgewood, Kentucky.

Dr. Choi is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Lynch Syndrome, Familial Colorectal Cancer, and Gamma Knife Radiosurgery.

He is actively involved in clinical research, co-authoring 39 peer reviewed articles and participating in 13 clinical trials. Dr. Choi is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MI

Hospital Affiliations

St Elizabeth Florence
St Elizabeth Edgewood
St Elizabeth Ft Thomas
St Elizabeth Grant

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medical Mutual
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Oncology-Edgewood Cancer Center-St. Elizabeth Healthcare
1 Medical Village Dr, Edgewood, KY 41017

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2026
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin
Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin
Enrollment Status: Terminated
Publish Date: January 30, 2025
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Leucovorin, Liposomal Irinotecan
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

39 Total Publications

The High-Energy Ion Telescope (HIT) for the Interstellar Mapping And Acceleration Probe (IMAP) Mission.
The High-Energy Ion Telescope (HIT) for the Interstellar Mapping And Acceleration Probe (IMAP) Mission.
Journal: Space science reviews
Published: October 12, 2025
Similar Doctors
Expertise in
22
conditions
Dr. Kasiani C. Myers
Hematology | Oncology
Expertise in
22
conditions
Dr. Kasiani C. Myers
Hematology | Oncology
Referral may be required

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (9.4 miles away)
513-636-4266
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients

Kasiani Myers is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Myers is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Shwachman-Diamond Syndrome, Congenital Aplastic Anemia, Fanconi Anemia, Aplastic Anemia, and Bone Marrow Transplant. Dr. Myers is currently accepting new patients.

Expertise in
13
conditions
Dr. Russell E. Ware
Hematology | Oncology
Expertise in
13
conditions
Dr. Russell E. Ware
Hematology | Oncology
Referral may be required

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (9.4 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Russell Ware is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Ware is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Splenectomy. Dr. Ware is currently accepting new patients.

Expertise in
15
conditions
Dr. Charles T. Quinn
Hematology | Oncology
Expertise in
15
conditions
Dr. Charles T. Quinn
Hematology | Oncology
Referral may be required

Office

3333 Burnet Ave # 7015, 
Cincinnati, OH 
 (9.4 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charles Quinn is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Quinn is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy. Dr. Quinn is currently accepting new patients.

Frequently Asked Questions about Dr. Minsig K. Choi

How do I make an appointment with Dr. Minsig K. Choi?

You can book an appointment with Dr. Minsig K. Choi by calling their office at 859-301-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Minsig K. Choi a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Minsig K. Choi is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Minsig K. Choi specialize in?

While Dr. Minsig K. Choi is a Oncology, they have specific expertise in Colorectal Cancer, Pancreatic Cancer, and Lynch Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Minsig K. Choi participate in research or clinical trials?

Yes. Dr. Minsig K. Choi has published 39 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Minsig K. Choi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Minsig K. Choi accept my insurance?

Dr. Minsig K. Choi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 859-301-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Choi's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile